TIMMA-R: An R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples

Bioinformatics

Volumn 31, Issue 11, 2015, Pages 1866-1868

  He, Liye ^a   Wennerberg, Krister ^a   Aittokallio, Tero ^a   Tang, Jing ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ALGORITHM; DRUG DEVELOPMENT; DRUG POTENTIATION; HUMAN; NEOPLASMS; SOFTWARE; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG DISCOVERY; DRUG SYNERGISM; HUMANS; NEOPLASMS; SOFTWARE;

EID: 84941656894     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btv067     Document Type: Conference Paper

References (16)

1. Al-Lazikani, B. et al. (2012) Combinatorial drug therapy for cancer in the postgenomic era. Nat. Biotechnol. , 30, 679-692.
2. Barretina, J. et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 483, 603-607.
3. Davis, M. I. et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. , 29, 1046-1051.
4. Dusa, A. (2010) A mathematical approach to the boolean minimization problem. Qual. Quant. , 44, 99-113.
5. Gaulton, A. et al. (2012) ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res. , 40, D1100-D1107.
6. Halling-Brown, M. D. et al. (2012) canSAR: An integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. , 40, D947-956.
7. Hopkins, A. L. (2008) Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. , 4, 682-690.
8. Lê, S. et al. (2008) FactoMineR: An R package for multivariate analysis. J. Stat. Softw. , 25, 1-18.
9. Pemovska, T. et al. (2013) Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. , 3, 1416-1429.
10. Sun, X. et al. (2013) High-throughput methods for combinatorial drug discovery. Sci. Transl. Med. , 5, 205rv1.
11. Tang, J. et al. (2013) Target inhibition networks: Predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput. Biol. , 9, e1003226.
12. Tang, J. et al. (2014) Making sense of large-scale kinase inhibitor bioactivity data sets: A comparative and integrative analysis. J. Chem. Inf. Model. , 54, 735-743.
13. Tyner, J. W. et al. (2013) Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. , 73, 285-296.
14. Vempati, U. D. et al. (2014) Metadata standard and data exchange specifications to describe, model, and integrate complex and diverse high-throughput screening data from the library of integrated network-based cellular signatures (LINCS). J. Biomol. Screen. , 19, 803-816.
15. Yang, W. et al. (2013) Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. , 41, D955-D961.
16. Zhao, J. et al. (2014) Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs. CPT Pharmacomet. Syst. Pharmacol. , 3, e102.